Labiotech.eu

News and Trends 11 May 2015

Are AbbVie and J&J already fighting to acquire Galapagos’ pipeline?

Ten years ago, Galapagos completed its initial public offering with a dual listing in Amsterdam and Brussels. Since then, Galapagos has grown, from 70 to more than 400 employees and from €70M to around €1.2Bn in market capitalization. Galapagos recently reported positive results with its JAK1 inhibitor in nearly 900 rheumatoid arthritis patients worldwide, triggering the interest […]

May 11, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 10 May 2015

Succesful Phase III for Indivior’s Schizophrenia treatment

Indivior obtained top-line results from its phase III clinical trial of RBP-7000, a candidate treatment for schizophrenia. Based on these successful outcomes, the company expects to submit a New Drug Application to the U.S. FDA for potential approval in 2017. Schizophrenia is a chronic, severe and disabling brain disorder that affects an estimated 26 million […]

May 10, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 8 May 2015

GSK sparks off the Gene Therapy resurgence

GlaxoSmithKline has become the first big pharma company to file a gene therapy approval case to the European Medicines Agency (EMA). The therapy, developed in collaboration with San Raffaele Hospital and the Telethon Foundation in Italy, is designed to cure a disease called adenosine deaminase (ADA) deficiency, which causes severe combined immunodeficiency syndrome, lead to serious infections and, ultimately, death. ADA […]

May 8, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 8 May 2015

MorphoSys acquired Lanthio, a Dutch Peptide Therapeutic company

MorphoSys has acquired the Dutch biopharmaceutical company Lanthio Pharma. Morphosys already held 19.98% of Lanthio Pharma and will now pay €20M to purchase all outstanding shares. Thanks to the transaction MorphoSys can add Lanthio Pharma’s lead compound, LP2, to its growing proprietary portfolio. The compound, a novel lanthipeptide in development for diabetic nephropathy and fibrotic […]

May 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 7 May 2015

Versantis, using liposomes technology to detoxify the body

What happens when your liver stops working? The toxins your body continuously produces will no longer be eliminated, transforming your own body in a remarkable poison factory. This problem, in reality, is quite common. Liver diseases affect more than 30 million Europeans, and kill more people than both diabetes and road accidents combined! Versantis, a Swiss based biotech […]

May 7, 2015 - 5 minutesmins - By Joachim Eeckhout

News and Trends 7 May 2015

Omeicos is moving forward with the appointment of D. Ulrich Dauer

Omeicos Therapeutics has appointed Dr. Ulrich Dauer as Chief Executive Officer. The company, that recently raised €6.2M, enrolled expert Dr. Dauer to advance on its atrial fibrillation treatment. Dr. Dauer will join Omeicos to bring additional leadership expertise as the company builds the infrastructure and capabilities needed to develop its lead therapeutic candidate for atrial […]

May 7, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 7 May 2015

Gilead acquired epigenetics-expert EpiTherapeutics

Gilead Sciences has acquired the small Danish biotech EpiTherapeutics for €57M. The epigenetics-expert has generated a library of small molecule inhibitors of gene transcription regulation than can be used for certain cancer treatments. The American company announced the signing of a definitive agreement to purchase the Danish company for €57M. EpiTherapeutics is developing innovative cancer […]

May 7, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 7 May 2015

Is the Biotech sector facing the issues of the Pharma Industry?

Currently, the pharma industry is going through a serious crisis, as the sector needs to review its economic model. On the other hand, the biotech sector often considered as the best way to innovate seems less promising than expected when it comes to putting drugs up on the market. Knowing this, it is likely that the biotech industry will face […]

May 7, 2015 - 5 minutesmins - By Nicolas Sainte-Foie

News and Trends 6 May 2015

Global Bioenergies produced its First batch of Isobutene in a record time

Global Bioenergies delivered the first batch of isobutene from renewable resources to its partner Arkema six months ahead of the projected schedule. Thanks to the cooperation of ARD’s, an affiliate of the French sugar producer Cristal Union, and Global Bioenergies’ teams, the scaling up of the process in the industrial pilot has been achieved in […]

May 6, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 6 May 2015

Flagship Ventures recruited a Dream Team composed of Astra Zeneca, Bayer and Nestlé

AstraZeneca, Bayer and Nestlé have entered Flagship Ventures’ ranks. The three big-shots will share their know how to support Flagship’s VentureLabs, its start-up incubator. Yet another victory for the American leading VC company that recently banked €478M. On March 26th, Flagship Ventures established its own personal record, putting together €478M in new funds. As Noubar Afeyan, […]

May 6, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 6 May 2015

Kymab secures €79.8 Million to develop its Antibody-Generating technology

British Kymab raised an additional €44.4M to its already very successful Series B financing. The cash was courtesy of Woodford Patient Capital Trust and Malin Corporation, which joined the Wellcome Trust and the Bill&Melinda Gates Foundation, the previous investors. The British biotech, a monoclonal antibody biopharmaceutical company, successfully raised an additional €44.4M to complete a […]

May 6, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 6 May 2015

Hello Tomorrow Challenge, a preview of the startup competition

Hello Tomorrow’s main goal is to create bridges between scientists, investors and entrepreneurs in all major technological fields. On 9th of April 2015, the team of Hello Tomorrow invited us to attend to their press conference given at the Ministry of Foreign Affairs in Paris. In April 2014, after three long years of preparation, the “First day […]

May 6, 2015 - 3 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Are AbbVie and J&J already fighting to acquire Galapagos’ pipeline?

Succesful Phase III for Indivior’s Schizophrenia treatment

GSK sparks off the Gene Therapy resurgence

MorphoSys acquired Lanthio, a Dutch Peptide Therapeutic company

Versantis, using liposomes technology to detoxify the body

Omeicos is moving forward with the appointment of D. Ulrich Dauer

Gilead acquired epigenetics-expert EpiTherapeutics

Is the Biotech sector facing the issues of the Pharma Industry?

Global Bioenergies produced its First batch of Isobutene in a record time

Flagship Ventures recruited a Dream Team composed of Astra Zeneca, Bayer and Nestlé

Kymab secures €79.8 Million to develop its Antibody-Generating technology

Hello Tomorrow Challenge, a preview of the startup competition

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!